300558 Betta Pharmaceuticals
- 37.82
- -0.23-0.60%
Betta Pharmaceuticals News
Betta Pharmaceuticals: Comparative table of amendments to the company's articles of association
Betta Pharmaceuticals: Announcement of Resolutions of the 14th Meeting of the Fourth Board of Directors
Betta Pharmaceuticals: Constitution of Betta Pharmaceuticals Co., Ltd. (May 2024)
Betta Pharmaceuticals: Announcement on changing the scope of business and amending the “Articles of Association”
Betta Pharmaceuticals: Notice on holding the 2024 First Extraordinary General Meeting of Shareholders
Betta Pharmaceuticals: 2023 dividend payment implementation announcement
Betta Pharmaceuticals: CITIC Securities Co., Ltd.'s inspection opinions on the storage and use of funds raised by Betta Pharmaceutical Co., Ltd. in 2023
Betta Pharmaceuticals: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Betta Pharmaceuticals: Legal Opinion of Guohao Law Firm (Hangzhou) on the 2023 Annual General Meeting of Shareholders of Betta Pharmaceutical Co., Ltd.
Betta Pharmaceuticals: 300558 Betta Pharmaceuticals Investor Relations Management Information 20240507
Betta Pharmaceuticals: CITIC Securities Co., Ltd.'s verification opinion on the use of temporarily idle funds raised by Betta Pharmaceuticals Co., Ltd. for cash management
Betta Pharmaceuticals: Notice on acceptance of BPI-16350 drug registration application
Betta Pharmaceuticals: Announcement on holding the 2023 Online Results Briefing
Betta Pharmaceuticals: An indicative announcement on BPI-16350 obtaining a phase III clinical trial summary report
Betta Pharmaceuticals: 300558 Betta Pharmaceuticals Investor Relations Management Information 20240423 (1)
Betta Pharmaceuticals: 300558 Betta Pharmaceuticals Investor Relations Management Information 20240423 (2)
Betta Pharmaceuticals: 2023 Supervisory Committee Work Report
Betta Pharmaceuticals: 2023 Independent Director Debriefing Report (JIANGNAN CAI)
Betta Pharmaceuticals: Special Report on Non-operating Capital Occupation and Other Related Capital Transactions in 2023
Betta Pharmaceuticals: Report of the Audit Committee of the Board of Directors on the Evaluation of the Accounting Firm's Performance in 2023
Analysis
Price Target
No Data
